Drug Trial Radar · NCT07546929
HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Feb 3, 2023
Primary completion
Oct 2026
Study completion Oct 2026
Sponsor
- Lead sponsor
- Housey Healthcare ULCIndustry
- Sponsor type
- Industry
- First posted
- Apr 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Blood sugar levels are controlled by insulin, a hormone made by cells in the pancreas. After a meal, carbohydrates are broken down into glucose which is absorbed from the intestine into the blood leading to a rise in glucose (blood sugar) which triggers the secretion of insulin. Insulin binds to cells in several tissues including liver, muscle, and fat, triggering cells to take up glucose and bring the blood glucose level back to normal. A high blood sugar level is known as diabetes. The most common form of diabetes, type 2 diabetes, is caused by insulin resistance; that is, a reduced ability of insulin to stimulate glucose uptake into cells. The body compensates for insulin resistance by making more insulin; type 2 diabetes occurs when the pancreas can no longer make enough insulin to control blood glucose. The high blood glucose and insulin levels lead to long-term complications such as heart attacks, kidney failure, reduced sensation and poor circulation in the feet and legs. High insulin levels also increase the incidence of cancers, stroke, and dementia. Reducing blood glucose levels with oral medications and insulin reduces risk of diabetic complications. There are several types of oral medications available for treating diabetes; however, they do not always control blood glucose adequately. In addition, these drugs have complications and are not used to treat insulin resistance and prediabetes - a condition when blood glucose is higher than normal but not high enough to be classified as diabetes. Prediabetes often progresses to diabetes over a period of months or years. Effective and safe treatments for insulin resistance may prevent the onset of diabetes or even reverse diabetes if diagnosed in its early stages before substantial damage to the pancreas has occurred. HP-211 is a botanical extract whose active ingredients are derived from herbs and vegetables present in normal diets. HP-211 has been shown in laboratory studies in cell culture, in animal studies, and in a previous Phase 1 study to enhance the ability of insulin to stimulate glucose uptake into cells. Thus, HP-211 may reduce the blood glucose and circulating insulin levels of subjects with type 2 diabetes after a meal. HP-211 may also reduce glucose and insulin responses to a greater extent in insulin-resistant as compared to insulin-sensitive subjects. Subjects will take 0, 1, 2 or 3 tablets of HP-211 in the morning and evening for 90 days. Hemoglobin A1c (HbA1c, or "A1c"), a measure of the average amount of glucose present in the blood, will be measured during the trial period.
Conditions
- Type 2 Diabetes
Interventions
HP-211Drug
HP-211 is an investigational botanical extract derived from Cichorium endivia var. latifolium, Lactuca sativa, and Artemisia dracunculus.
PlaceboDrug
Matching placebo administered orally twice daily (BID).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Hemoglobin A1c (HbA1c)Time frame: After 12 weeks of treatment.
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
Alliance Clinical Canoga Park (Hope Clinical Research)
Canoga Park, California · Recruiting
Universal Axon Clinical Research
Doral, Florida · Recruiting
Velocity Clinical Research New Smyrna Beach
Edgewater, Florida · Recruiting
Southwest General Healthcare Center
Fort Myers, Florida · Recruiting
Avantis Clinical Research
Miami, Florida · Recruiting
IMIC Research
Miami, Florida · Recruiting
South Broward Research
Miramar, Florida · Recruiting
David Kavtaradze MD InC
Cordele, Georgia · Recruiting
AMR Clinical - El Dorado
El Dorado, Kansas · Recruiting
Tandem Clinical Research (Interspond)
Marrero, Louisiana · Recruiting
Arcturus Healthcare, PLC, Troy Internal Medicine Research Division
Troy, Michigan · Recruiting
Velocity Clinical Research Norfolk
Norfolk, Nebraska · Recruiting
Alliance Clinical Las Vegas (Excel Clinical Research)
Las Vegas, Nevada · Recruiting
Diabetes & Endocrinology Associates of Stark County, Inc.
Canton, Ohio · Recruiting
Advanced Medical Research
Maumee, Ohio · Recruiting
Velocity Clinical Research Providence
East Greenwich, Rhode Island · Recruiting
Velocity Clinical Research Dallas
Dallas, Texas · Recruiting
Tekton Research
Irving, Texas · Recruiting
Alliance Clinical Lewisville (Epic Clinical Research)
Lewisville, Texas · Recruiting
Tekton Research
McKinney, Texas · Recruiting
Tekton Research
San Antonio, Texas · Recruiting
Simcare Medical Research, LLC.
Sugar Land, Texas · Recruiting
Velocity Clinical Research Waco
Waco, Texas · Recruiting
Burke Internal Medicine & Research
Burke, Virginia · Recruiting
Tekton Research
Midlothian, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.